Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/16549716.2021.1892309 http://scihub22266oqcxt.onion/10.1080/16549716.2021.1892309 33627051!7919886!33627051     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Glob+Health+Action 2021 ; 14 (1): 1892309 Nephropedia Template TP {{tp|p=33627051|t=2021. Making a COVID-19 vaccine that works for everyone: ensuring equity and inclusivity in clinical trials |pdf=|usr=}}{{33627051}} gab.com Text Making a COVID-19 vaccine that works for everyone: ensuring equity and inclusivity in clinical trials JO: Glob Health Action http://www.kidney.de/pget.php?&tw=1&pmid=33627051 #FOAvip Coronavirus disease 2019 (COVID-19) mortality and morbidity have been shown to increase with deprivation and impact non-White ethnicities more severely. Despite the extra risk Black, Asian and Minority Ethnicity (BAME) groups face in the pandemic, our current medical research system seems to prioritise innovation aimed at people of European descent. We found significant difficulties in assessing baseline demographics in clinical trials for COVID-19 vaccines, displaying a lack of transparency in reporting. Further, we found that most of these trials take place in high-income countries, with only 25 of 219 trials (11.4%) taking place in lower middle- or low-income countries. Trials for the current best vaccine candidates (BNT162b2, ChadOx1, mRNA-173) recruited 80.0% White participants. Underrepresentation of BAME groups in medical research will perpetuate historical distrust in healthcare processes, and poses a risk of unknown differences in efficacy and safety of these vaccines by phenotype. Limiting trial demographics and settings will mean a lack of global applicability of the results of COVID-19 vaccine trials, which will slow progress towards ending the pandemic. Twit Text FOAVip Making a COVID-19 vaccine that works for everyone: ensuring equity and inclusivity in clinical trials ????Glob Health Action http://www.kidney.de/pget.php?&tw=1&pmid=33627051 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33627051 #FOAvip English Wikipedia <ref>{{Cite pmid|33627051}}</ref> Making a COVID-19 vaccine that works for everyone: ensuring equity and inclusivity in clinical trials #MMPMID33627051 Pepperrell T; Rodgers F; Tandon P; Sarsfield K; Pugh-Jones M; Rashid T; Keestra S Glob Health Action 2021[Jan]; 14 (1): 1892309 PMID33627051show ga Coronavirus disease 2019 (COVID-19) mortality and morbidity have been shown to increase with deprivation and impact non-White ethnicities more severely. Despite the extra risk Black, Asian and Minority Ethnicity (BAME) groups face in the pandemic, our current medical research system seems to prioritise innovation aimed at people of European descent. We found significant difficulties in assessing baseline demographics in clinical trials for COVID-19 vaccines, displaying a lack of transparency in reporting. Further, we found that most of these trials take place in high-income countries, with only 25 of 219 trials (11.4%) taking place in lower middle- or low-income countries. Trials for the current best vaccine candidates (BNT162b2, ChadOx1, mRNA-173) recruited 80.0% White participants. Underrepresentation of BAME groups in medical research will perpetuate historical distrust in healthcare processes, and poses a risk of unknown differences in efficacy and safety of these vaccines by phenotype. Limiting trial demographics and settings will mean a lack of global applicability of the results of COVID-19 vaccine trials, which will slow progress towards ending the pandemic. |*COVID-19 Vaccines[MESH] |*Clinical Trials as Topic[MESH] |*Ethnicity[MESH] |*Health Equity[MESH] |*Minority Groups[MESH] |COVID-19/*prevention & control[MESH] |Communicable Disease Control[MESH] |Female[MESH] |Humans[MESH] |Male[MESH] |Pandemics/prevention & control[MESH]Making a COVID-19 vaccine that works for everyone: ensuring equity and(epmc).pdf DeepDyve Pubget Overpricing